Eli Lilly & Co. raised its full-year sales forecast as demand for its blockbuster obesity and diabetes drugs continues to surge. Speaking on "Bloomberg Open Interest," Muller also discusses the implications for Novo Nordisk. (Source: Bloomberg)
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.